LAVAL, QC, April 21, 2026 /CNW/ - In recognition of AML World Awareness Day, Servier Canada is highlighting the progress made in precision medicine for Acute Myeloid Leukemia (AML). With TIBSOVO(R) ...
Genomic profiling enables therapy individualization when actionable mutations (FLT3, NPM1, IDH1/2, TP53) are present, moving ...
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today highlighted data presented at the American Association ...
A new Phase 1B/2 trial treated patients with acute myeloid leukemia (AML) in a drug regimen combination of Annamycin and Ara-C. The evaluation of Annamycin in combination with Ara-C (cytarabine) has ...
A new analysis by researchers at The University of Texas MD Anderson Cancer Center demonstrates that a combination therapy ...
SELLAS Life Sciences (SLS) is rated 'Hold' due to pending phase 3 REGAL data for GPS in AML after CR2, a major 2026 catalyst.
Sellas Life Sciences’ investigational CDK9 inhibitor has scored in a midstage acute myeloid leukemia (AML) study, demonstrating an overall response rate (ORR) more than double the 20% goal. The ...
LYT-200 plus HMA at 12 mg/kg delivered 45.5% ORR in 11 R/R HR-MDS patients, including 27.3% CRs, despite 100% prior HMA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results